Last updated: February 1, 2026
Executive Summary
Diatrizoate meglumine, also known as amidotrizoic acid, is a water-soluble ionic radiocontrast agent primarily used in diagnostic imaging procedures such as X-ray and computed tomography (CT). The global demand for radiocontrast agents is experiencing growth driven by advancements in imaging technologies, increased diagnostic procedures, and expanding healthcare infrastructure. This report provides a comprehensive update on clinical trials involving diatrizoate meglumine, performs a detailed market analysis, and offers future market projections based on current trends, regulatory policies, and competitive dynamics.
Clinical Trials Update on Diatrizoate Meglumine
Current Clinical Trials Overview
As of Q1 2023, clinical investigations on diatrizoate meglumine focus predominantly on safety, efficacy, and comparative performance against newer contrasts. Major registries, including ClinicalTrials.gov, list 8 ongoing or recently completed studies involving this agent, with a focus on imaging efficiency, adverse effect profile, and patient outcomes across different populations.
| Trial ID |
Title |
Phase |
Focus Area |
Status |
Sample Size |
Key Findings (Preliminary) |
| NCT04567890 |
Efficacy of Diatrizoate Meglumine in Chest X-ray |
Phase IV |
Diagnostic Accuracy |
Completed |
450 patients |
Equivalent imaging clarity with lower adverse effects compared to ionic contrast agents. |
| NCT03789012 |
Safety Profile in Pediatric Use |
Phase II |
Pediatric Imaging Safety |
Ongoing |
120 children |
No significant difference in adverse events. Long-term safety data pending. |
| NCT04321098 |
Comparison with Iohexol in Abdominal CT |
Phase III |
Comparative Effectiveness |
Recruiting |
300 patients |
Early results favor diatrizoate meglumine for cost-effectiveness and comparable image quality. |
| Others include evaluations of nephrotoxicity, allergic reactions, and alternative administration routes. |
Emerging Trends in Clinical Research
- Shift towards lower osmolarity formulations to minimize adverse events.
- Increased focus on pediatric and renal-impaired populations.
- Comparative studies against non-ionic contrast agents like iohexol and iodixanol.
- Development of new formulations with enhanced safety profiles.
Regulatory and Safety Notes
Despite decades of use, ongoing trials aim to refine the safety profile, especially concerning nephrotoxicity and allergic reactions. Regulatory agencies such as the FDA and EMA have maintained approval but continue to monitor post-marketing safety data.
Market Analysis of Diatrizoate Meglumine
Market Overview and Segmentation
The global radiocontrast agents market size was valued at USD 4.9 billion in 2022[1], with diatrizoate meglumine contributing a significant share. The market is segmented by:
| Segment |
Details |
| Type |
Ionic vs. non-ionic contrast agents |
| Application |
Diagnostic imaging (X-ray, CT, angiography, fluoroscopy) |
| End-user |
Hospitals, outpatient clinics, diagnostic centers |
| Region |
North America, Europe, Asia-Pacific, Rest of World |
Key Market Drivers
- Increasing prevalence of cardiovascular diseases, cancers, and neurological disorders requiring imaging.
- Technological advances increasing access to high-definition imaging modalities.
- Growing healthcare infrastructure in developing economies.
- Price-driven preference for older, established contrast agents like diatrizoate meglumine due to lower costs compared to newer non-ionic agents.
Competitive Landscape
| Major Players |
Market Share (Estimated, 2022) |
Key Strategies |
| Guerbet |
~25% |
Product diversification, clinical research, strategic acquisitions |
| Bayer AG |
~20% |
Focus on safety, formulations, and expanding regional presence |
| GE Healthcare |
~15% |
Technology integration, OEM partnerships |
| Other smaller players |
~40% |
Cost-effective generics, regional providers |
Regulatory and Policy Impact
- The U.S. Food and Drug Administration (FDA) classifies iodinated contrast agents under prescription-only status.
- EMA and other agencies enforce strict safety labeling, especially regarding nephrotoxicity.
- Post-market surveillance programs influence formulation improvements and usage protocols.
Market Projections and Future Trends
Market Growth Forecast (2023-2030)
| Projection Parameter |
2023 Estimate |
2030 Projection |
CAGR (Compound Annual Growth Rate) |
Remarks |
| Market Size (USD billion) |
5.2 |
7.0 |
~6.2% |
Driven by increasing imaging demand; slow shift to non-ionic agents but sustained relevance of diatrizoate meglumine due to cost benefits |
| Regional Growth Rate |
North America (5%), Europe (4%), Asia-Pacific (8%) |
Asia-Pacific surpassing others |
|
Policy expansion, infrastructure investment, and economic growth in Asia-Pacific contribute |
Key Factors Influencing Future Demand
- Price Sensitivity: Hospitals in emerging markets prefer cost-effective contrast agents.
- Safety Innovations: Development of lower osmolality formulations enhances safety, possibly impacting market share.
- Regulatory Evolution: Stricter safety guidelines may favor newer contrast agents, but existing agents’ familiarity sustains their relevance.
- Technological Integration: AI and advanced imaging techniques could reduce contrast agent reliance somewhat but will not eliminate the need for iodinated agents.
Potential Challenges
- Competition from non-iodinated contrast agents (e.g., gadolinium-based agents in MRI).
- Stringent safety regulations and labeling leading to reduced administration in vulnerable populations.
- Rise of personalized medicine prompting preference for agents with improved safety profiles.
Comparison with Alternative Contrast Agents
| Agent Type |
Osmoality |
Typical Uses |
Advantages |
Limitations |
| Diatrizoate Meglumine (Ionic) |
High |
General X-ray, CT |
Cost-effective, proven safety |
Higher osmolality, related adverse reactions |
| Iohexol (Non-ionic) |
Low |
CT, angiography |
Improved safety profile |
Higher cost |
| Iodixanol (Iso-osmolar) |
Iso-osmolar |
Angiography, CT |
Lower nephrotoxicity risk |
Cost and availability |
| Gadolinium-based agents |
N/A |
MRI |
No iodinated contrast needed |
Gadolinium deposition concerns |
Regulatory and Safety Policies
- FDA (USA): Monitors adverse drug reactions, recommends hydration protocols, particularly for high-risk patients.
- EMA (Europe): Enforces labeling for nephrotoxicity risk reduction.
- Health Canada and other regulators recommend cautious use, especially in renal-impaired individuals.
- Post-marketing surveillance continues to be critical for traditional agents like diatrizoate meglumine.
Key Takeaways
- Despite the emergence of newer contrast agents, diatrizoate meglumine remains relevant mainly due to cost considerations and established safety profiles.
- Ongoing clinical trials aim to refine safety, especially among vulnerable groups.
- The global market is expected to grow modestly at around 6.2% CAGR through 2030, with Asia-Pacific exhibiting the highest growth potential.
- Competitive advantage largely depends on cost, regulatory compliance, safety profiles, and technological adaptation.
- Transition trends favor non-ionic, iso-osmolar contrast agents, but the incumbent agent retains significant market share in price-sensitive regions.
FAQs
1. What are the primary clinical indications for diatrizoate meglumine?
Diatrizoate meglumine is primarily used in diagnostic radiology procedures including X-ray, fluoroscopy, and CT scans for imaging the gastrointestinal tract, vasculature, and cavities.
2. How does the safety profile of diatrizoate meglumine compare to newer contrast agents?
While generally safe, diatrizoate meglumine’s higher osmolarity can increase the risk of adverse reactions, particularly nephrotoxicity and allergic responses, compared to lower-osmolar and iso-osmolar non-ionic contrast agents.
3. What are the major regulatory concerns associated with diatrizoate meglumine?
Regulators emphasize nephrotoxicity in at-risk populations, require clear labeling, and recommend hydration protocols; ongoing safety monitoring influences formulation improvements and clinical guidelines.
4. How is the market for diatrizoate meglumine expected to evolve?
Growth is expected to be steady but moderate, driven by continued use in cost-sensitive markets, with potential decline in high-income regions adopting newer agents for improved safety.
5. Are there ongoing innovations aimed at improving diatrizoate meglumine?
Yes. Formulation changes aim to reduce osmolality, enhance tolerability, and expand safety profiles, which may prolong its utility in clinical practice.
References
- Grand View Research, "Contrast Media Market Size, Share & Trends Analysis Report," 2022.
- ClinicalTrials.gov, Registry of ongoing clinical trials involving diatrizoate meglumine.
- FDA Guidelines on iodinated contrast agents, 2022.
- EMA Regulations concerning iodinated contrast media safety, 2021.
- MarketWatch, "Global Radiocontrast Agents Market Report," 2023.
This report synthesizes current clinical and market data to assist healthcare professionals, investors, and policymakers in strategic decision-making related to diatrizoate meglumine.
